Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EPS (Basic): 2011-2025

Historic EPS (Basic) for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to -$0.02.

  • Fennec Pharmaceuticals' EPS (Basic) rose 90.48% to -$0.02 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.25, marking a year-over-year decrease of 525.00%. This contributed to the annual value of -$0.02 for FY2024, which is 96.67% up from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported EPS (Basic) of -$0.02 as of Q3 2025, which was up 81.82% from -$0.11 recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' EPS (Basic) ranged from a high of $0.47 in Q1 2024 and a low of -$0.40 during Q4 2022.
  • Its 3-year average for EPS (Basic) is -$0.07, with a median of -$0.10 in 2023.
  • Within the past 5 years, the most significant YoY rise in Fennec Pharmaceuticals' EPS (Basic) was 304.35% (2024), while the steepest drop was 200.00% (2024).
  • Quarterly analysis of 5 years shows Fennec Pharmaceuticals' EPS (Basic) stood at -$0.16 in 2021, then tumbled by 93.75% to -$0.40 in 2022, then surged by 75.00% to -$0.10 in 2023, then increased by 20.00% to -$0.08 in 2024, then spiked by 90.48% to -$0.02 in 2025.
  • Its EPS (Basic) stands at -$0.02 for Q3 2025, versus -$0.11 for Q2 2025 and -$0.04 for Q1 2025.